Tags

Type your tag names separated by a space and hit enter

Rational use of tocilizumab in COVID-19.
Ann Rheum Dis. 2020 Jul 31 [Online ahead of print]AR

Authors+Show Affiliations

Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India.Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India sharmashefali@hotmail.com.

Pub Type(s)

Letter

Language

eng

PubMed ID

32737106

Citation

Jain, Siddharth, and Shefali Khanna Sharma. "Rational Use of Tocilizumab in COVID-19." Annals of the Rheumatic Diseases, 2020.
Jain S, Sharma SK. Rational use of tocilizumab in COVID-19. Ann Rheum Dis. 2020.
Jain, S., & Sharma, S. K. (2020). Rational use of tocilizumab in COVID-19. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2020-218519
Jain S, Sharma SK. Rational Use of Tocilizumab in COVID-19. Ann Rheum Dis. 2020 Jul 31; PubMed PMID: 32737106.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rational use of tocilizumab in COVID-19. AU - Jain,Siddharth, AU - Sharma,Shefali Khanna, Y1 - 2020/07/31/ PY - 2020/07/04/received PY - 2020/07/11/revised PY - 2020/07/15/accepted PY - 2020/8/2/entrez KW - antirheumatic agents KW - biological therapy KW - communicable diseases, imported KW - cytokines KW - inflammation JF - Annals of the rheumatic diseases JO - Ann. Rheum. Dis. SN - 1468-2060 UR - https://www.unboundmedicine.com/medline/citation/32737106/Rational_use_of_tocilizumab_in_COVID-19 L2 - https://ard.bmj.com/lookup/pmidlookup?view=long&pmid=32737106 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.